Citadel Advisors
IMRX icon

Citadel Advisors’s Immuneering IMRX Stock Holding History

Citadel Advisors’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Sell
61,600
-700
-1% -$3.54K ﹤0.01% 11069
2026
Q1 		$328K Buy
62,300
+45,700
+275% +$234K ﹤0.01% 10275
2025
Q4 		$109K Buy
+16,600
New +$107K ﹤0.01% 11564

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors's IMRX Position: Q2 2026 in Review

Citadel Advisors reduced its Immuneering (IMRX) stake by 14% in Q2 2026, selling an estimated $308K and leaving 386,411 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #6633.

Citadel Advisors first reported a position in IMRX in Q3 2021 and has held it in 16 quarters since. The position peaked at $52.4M in Q3 2021. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Citadel Advisors held 386,411 shares of Immuneering worth $1.93M as of Q2 2026.
  • Citadel Advisors sold 60,867 Immuneering shares in Q2 2026, an estimated $308K.
  • Immuneering made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6633 holding.
  • Citadel Advisors first reported a position in Immuneering in Q3 2021 and has held it in 16 quarters since.
  • Citadel Advisors's Immuneering position peaked at $52.4M in Q3 2021.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.